

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number  
**WO 2005/049846 A2**

(51) International Patent Classification<sup>7</sup>: **C12N 15/869**,  
A61K 35/76, C12N 7/01, C07K 14/82, C12N 15/11,  
A61K 48/00

**RESEARCH** [US/US]; Memorial Sloane Kettering Cancer Center, 1275 York Avenue, New York, New York 10021 (US).

(21) International Application Number:  
PCT/GB2004/004908

(71) Applicants and

(72) Inventors: **BROWN, Susanne Moira** [GB/GB]; Crusade Laboratories Limited, PO Box 1716, Glasgow Strathclyde G51 4WF (GB). **DUNN, Paul** [GB/GB]; Crusade Laboratories Limited, PO Box 1716, Glasgow Strathclyde G51 4WF (GB). **SINGH, Bhuvanesh** [US/US]; 86-79 Sancho Street, Holliswood, New York, New York 11423 (US). **GANLY, Ian** [GB/US]; 504 East 63rd Street, Apartment 26S, New York, New York 10021 (US).

(22) International Filing Date:  
17 November 2004 (17.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0326798.6 17 November 2003 (17.11.2003) GB  
60/541,308 3 February 2004 (03.02.2004) US


(74) Agents: **CLEGG, Richard** et al.; Mewburn Ellis LLP, York House, '23 Kingsway, London Greater London WC2B 6HP (GB).

(71) Applicants (for all designated States except US):  
**CRUSADE LABORATORIES LIMITED** [GB/GB];  
PO Box 1716, Glasgow Strathclyde G51 4WF (GB).  
**SLOANE-KETTERING INSTITUTE FOR CANCER**

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

[Continued on next page]

(54) Title: **MUTANT VIRUSES**



(57) Abstract: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.

**BEST AVAILABLE COPY**

WO 2005/049846 A2



MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*